Life sciences jobs pack 2-for-1 punch
While life sciences companies don’t rack up huge jobs numbers, their relatively high pay means that every job they create is worth two in the rest of the private sector.
While life sciences companies don’t rack up huge jobs numbers, their relatively high pay means that every job they create is worth two in the rest of the private sector.
The Obama administration’s delays of Obamacare’s employer mandate penalties mean it will be another year or two before hospitals see the additional revenue the law was supposed to bring them.
Indianapolis Public Schools should immediately consider selling five of its buildings and work with IndyGo to transport students, according to a study by the Indianapolis Chamber of Commerce.
The bulk of the money, to be spent over five years, will go to a 134,000-square-foot health sciences center, which will provide training space for the university’s nursing, physical therapy and other health care students.
John Cannon, the man credited with righting the ship at WellPoint Inc., was terminated without cause this week, the company disclosed in a securities filing Friday morning.
House Bill 1258 would allow the large health insurer Anthem Blue Cross and Blue Shield to launch a pilot program using the Live Health Online technology it has developed with Massachusetts-based software firm American Well Corp.
Sen. Luke Kenley scuttled a pilot program of state-funded preschool vouchers for low-income families on Feb. 19, instead sending it to a summer committee to investigate 10 questions he said will help make sure Indiana launches a worthwhile program.
Even if Gov. Mike Pence and Obama’s health secretary can’t come to terms this weekend, there are ideas bouncing around the state legislature that suggest other ways Indiana could expand coverage to low-income Hoosiers.
Shares of Eli Lilly and Co. rose as much as 3.8 percent Wednesday morning after the Indianapolis-based drugmaker revealed that an experimental drug boosted overall survival among lung cancer patients in a large trial.
Lawmakers Young and Donnelly push restoration of 40-hour definition of full-time, but critics say their bills would gut Obamacare’s employer mandate and lead to a decline in employer insurance coverage.
Rich employer benefits are not always so attractive, sick patients are not always money losers for insurers, and hospitals and doctors are now health care preventers rather than health care providers. This is the bizarre world to which Obamacare has brought us.
The latest enrollment data from the Obamacare exchanges show that three out of four Hoosiers are purchasing decent coverage—not the super high-deductible plans that concerned hospitals.
Nearly two-thirds of the state’s nursing homes are now participating in partnerships with county-owned hospitals that effectively double their profit margins.
Fritz French and Richard DiMarchi, the former leaders of Marcadia Biotech, have teamed up to launch the diabetes drug development firm Calibrium LLC.
Ever since World War 2, when employers started using health benefits to compete for workers, the less employees had to pay toward health insurance premiums the more attractive the benefits. But under Obamacare, this axiom will not always be true.
Venture capitalists and angel investors put a combined $31.9 million into 18 life sciences companies last year, with some of the largest amounts going to Nextremity Solutions, hc1.com and FAST BioMedical.
Carmel-based developer Mainstreet Property Group announced Friday that it will open seven more health care facilities for Hoosier seniors this year and another 17 on top of that by 2016.
U.S. sales are plunging for Roche Diagnostics Corp. and its fellow makers of diabetes-care devices because of lower reimbursements from the federal Medicare program. In five years, two of the four largest companies will have sold or closed their diabetes businesses, according to two industry analysts.
The new two-year agreement gives UnitedHealthcare discounted rates retroactive to Jan. 1. Such discounts, which insurers negotiate with hospital systems, reduce prices 30 percent or more.
This year will be ugly for Eli Lilly and Co., after the recent loss of two blockbusters, but it also gives Lilly an opportunity it hasn’t really had for nearly a decade: grow sales and profit by launching new drugs.